MDMXF (Medmix AG) Change In Receivables: $-10.5 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDMXF Medmix AG MDMXF
67 GF Score
Price $17.40
GF Value $17.94
! 6 Warning Signs
View Full Analysis

What is Medmix AG Change In Receivables?

Medmix AG MDMXF 67 Change In Receivables is $-10.5 Mil as of Jun. 2026. GuruFocus rates MDMXF with a GF Score™ of 67/100 and a GF Value™ of $17.94. The stock has 6 warning signs investors should review.

Medmix AG's change in receivables for the quarter that ended in Jun. 2026 was $-6.9 Mil. It means Medmix AG's Accounts Receivable increased by $6.9 Mil from Dec. 2025 to Jun. 2026 .

Medmix AG's change in receivables for the fiscal year that ended in Dec. 2025 was $-15.3 Mil. It means Medmix AG's Accounts Receivable increased by $15.3 Mil from Dec. 2024 to Dec. 2025 .

Medmix AG's Accounts Receivable for the quarter that ended in Jun. 2026 was $73.1 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Medmix AG's Days Sales Outstanding for the six months ended in Jun. 2026 was 49.71.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Medmix AG's liquidation value for the six months ended in Jun. 2026 was $-427.6 Mil.

Medmix AG  (OTCPK:MDMXF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Medmix AG's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=73.064/268.235*91
=49.71

2. In Ben Graham's calculation of liquidation value, Medmix AG's accounts receivable are only considered to be worth 75% of book value:

Medmix AG's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=139.247-672.714+0.75 * 73.064+0.5 * 102.214
=-427.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medmix AG Change In Receivables Related Terms

Medmix AG Change In Receivables Historical Data

* Premium members only.

The historical data trend for Medmix AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medmix AG Change In Receivables Chart

Medmix AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial -3.15 -41.76 2.31 13.91 -15.31

Medmix AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.25 17.16 -11.44 -3.64 -6.88
MDMXF
67GF Score
Medmix AG MDMXF
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medmix AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-10.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-10.5 Mil mean?
Medmix AG (MDMXF) has a Change In Receivables of $-10.5 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Medmix AG and its competitors.
Is Medmix AG's Change In Receivables too high?
Medmix AG's current Change In Receivables is $-10.5 Mil. Overall, Medmix AG has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Medmix AG's Change In Receivables compare to GEV and ETN?
Medmix AG's Change In Receivables of $-10.5 Mil can be compared against companies in the Industrial Products industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for an Industrial Products company?
A good Change In Receivables depends on the Industrial Products industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Medmix AG and its competitors. Medmix AG's current Change In Receivables is $-10.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medmix AG stock overvalued right now?
Medmix AG (MDMXF) has a current Change In Receivables of $-10.5 Mil. The stock's GF Value™ is $17.94, compared to a current price of $17.40 — trading 3% below its estimated fair value. The current Change In Receivables is $-10.5 Mil. Medmix AG's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Medmix AG (MDMXF), the current Change In Receivables is $-10.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medmix AG (MDMXF) Overvalued in 2026?

Based on GuruFocus' analysis, Medmix AG stock appears to be undervalued. The current stock price of $17.40 is trading 3% below its estimated GF Value™ of $17.94.

Key valuation signals for MDMXF:

  • Change In Receivables: $-10.5 Mil
  • GF Value™: $17.94 vs. price of $17.40 (3% below fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the MDMXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medmix AG Business Description

Other Exchanges MEDXz:UKMEDX:Switzerland
Address Neuhofstrasse 20, Baar, CHE, 6340
Medmix AG designs and produces high-precision delivery devices for the healthcare, consumer and industrial segments. Its segments are Healthcare, Consumer & Industrial, and Others. The Healthcare segment focuses on delivery devices for the drug delivery, surgery, and dental markets, including injection pens for subcutaneous drug delivery, surgical delivery devices, and mixing and delivery systems for the dental consumable industry. The Consumer & Industrial segment focuses on delivery devices used for industrial applications such as adhesives in construction, electronics, automotive, and aerospace, as well as consumer markets such as beauty and microbrush applications. The company operates in Europe, the Middle East and Africa, the Americas, and Asia-Pacific.
67GF Score

Get the complete analysis for MDMXF

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.40
Price
$17.94
GF Value